Skip to main content
Toggle navigation
Login
Search
Home
Browse by Poster Title
Home
Browse by Poster Title
Browse by Poster Title
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
#
Sort by
#
Sort by
Title
A
S-114
A Bayesian Population Pharmacokinetic Analysis of Oritavancin in Pediatric Patients with Skin Infections
Favorite
M-044
A Case Study Showcasing the Impact of the InSilicoTrials Platform on Obesity Clinical Trials
Favorite
M-114
A Dose That Fits All: Model-Based Insights into the Impact of Obesity on Midazolam Oromucosal Pharmacokinetics in Adults
Favorite
T-103
A Fisher Information Matrix-based Analysis to Determine Precision of Estimated PK Parameters for Reduced Sample Sizes in Pediatric Studies in Rare Diseases
Favorite
T-089
A Framework for Developing a Virtual Murine Cohort: Applications to Adoptive Cell Therapy in Bladder Cancer
Favorite
S-095
A Julia Package for Traceable and Reproducible Models in Quantitative Systems Pharmacology
Favorite
T-088
A Mechanistic Pharmacokinetic/Pharmacodynamic Model for CD19 Targeting Therapies for Autoimmune Diseases
Favorite
T-050
A Mechanistic Pharmacokinetic-Pharmacodynamic Model Framework for Degrader-Antibody Conjugates
Favorite
T-028
A Mechanistic Pharmacokinetics and Pharmacodynamics (PK/PD) Platform Model for Induced proximity-based therapeutics - PROTACs
Favorite
M-101
A minimal model to support a CAR T-cell therapy development platform
Favorite
S-012
A Minimal-Quantitative Systems Pharmacology Model for Dual-Targeting Bispecific T Cell Modulators in Immuno-Oncology for Solid Tumors
Favorite
T-057
A Model Based Meta Analysis of Ulcerative Colitis for Clinical Remission
Favorite
T-057
A Model Based Meta Analysis of Ulcerative Colitis for Clinical Remission
Favorite
T-029
A Model-Based Meta-Analysis Framework to Predict and Manage ADC-Related Grade 3+ Neutropenia Across Clinical Studies
Favorite
M-022
A multi-model strategy in R to address cytopenia
Favorite
T-109
A Multi-route, Multi-formulation Population Pharmacokinetic Framework for THC and 11-OH-THC Reflecting Real-World Use
Favorite
S-009
A novel approach for predicting the efficacy of updated vaccines when the correlate of protection is known
Favorite
S-116
A Novel Bayesian Adaptive Design for Phase I Dose Escalation with Improved Efficiency and Accuracy in Estimation of Maximum Tolerated Dose
Favorite
M-082
A Novel Estimation Method for a Globally Unidentifiable Linear Compartment Models Using Bayesian Constraint Relaxation
Favorite
M-082
A Novel Estimation Method for a Globally Unidentifiable Linear Compartment Models Using Bayesian Constraint Relaxation
Favorite
T-056
A novel mechanistic mathematical model of liver transplant immune dynamics predicts important drivers of patient outcome
Favorite
S-025
A Novel Multi-Agent Framework for Automated Pharmacometric Analysis with Human-Like Reasoning
Favorite
S-088
A pediatric PBPK model of atropine gel to predict atropine levels in children with neurological disorders after administration to oral cavity
Favorite
M-028
A Pharmacometrics Strategy for Ensuring Compatibility of Exposure-Response Analysis with Clinical Study Report: Enhancing Accuracy, Traceability, and Transferability Through Variable Mapping Specification (VMS)
Favorite
M-039
A Physiologically Based Pharmacokinetic Framework for Predicting Drug Exposure in the Female Reproductive Tract
Favorite
S-038
A Physiologically Based Pharmacokinetic Model of Ceftriaxone in Healthy Adults and Pregnant Women
Favorite
T-015
A pipeline for generating large virtual dog populations to predict preclinical drug-induced liver injury
Favorite
T-073
A PK/PD Model to Evaluate Uricosuric Clinical Efficacy versus Therapeutic Window for Treatment of Gout
Favorite
S-101
A Population Pharmacokinetic Approach to Prospectively Assess Vancomycin Pharmacokinetics in Adult Jordanian Patients: a Step towards Personalized Dosing
Favorite
T-081
A Population PK Approach to Evaluate Plasma and ELF Exposure Changes Following Co-administration of Spectinamide 1599 and Pyrazinamide in Mice
Favorite
M-024
A Population PK-PD Model-Informed Approach to Guide Formulation Development
Favorite
S-087
A Quantitative Systems Pharmacology (QSP) Model Platform to Study the Impact of Intra-tumoral Heterogeneity on Antibody-Drug Conjugate (ADC) Treatment Efficacy
Favorite
M-037
A quantitative systems pharmacology model of felzartamab, an anti-CD38 antibody, to link immune cell and pharmacodynamic responses in immune mediated diseases
Favorite
T-024
A Scalable, Traceable and Integrated Tool for Large QSP Models Calibration
Favorite
T-061
A semi-mechanistic PKPD model of CSL112 harmonizes the differential cholesterol efflux capacities (CEC) of high-density lipoprotein across different dose groups
Favorite
S-041
A simulation-based Comparison of Approaches to Safety Outcome Estimation in Special Populations
Favorite
S-078
A Translational QSP Modeling Framework Demonstrates Tissue-Level Pharmacokinetics Do Not Predict the Clinical Efficacy of FTC/TDF PrEP
Favorite
S-063
A Translational Quantitative Systems Pharmacology Framework For Alpha-Synuclein-Targeted Parkinson’s Therapies Integrating Pharmacokinetics, Neuronal Biophysics, And Pathological Network Oscillations
Favorite
S-063
A Translational Quantitative Systems Pharmacology Framework For Alpha-Synuclein-Targeted Parkinson’s Therapies Integrating Pharmacokinetics, Neuronal Biophysics, And Pathological Network Oscillations
Favorite
M-097
Accounting for Temporal Differences in Fetal Exposure during Pregnancy using Masking
Favorite
T-011
Accurate modeling of ACTH and cortisol dynamics for Cushing’s disease treatment
Favorite
T-014
ACS-SIMULATOR: A Shiny Application for Guiding Antenatal Corticosteroid Administration in Pregnant Women
Favorite
T-013
Adaptable PBPK-QSP gene therapy model applied to i.v. administration of AAV-2 across different species
Favorite
T-093
Adjusted Ideal Body Weight Dosing Reduces Pharmacokinetic Variability of the PD-L1 Targeted Antibody-Drug Conjugate PDL1V (PF-08046054)
Favorite
T-093
Adjusted Ideal Body Weight Dosing Reduces Pharmacokinetic Variability of the PD-L1 Targeted Antibody-Drug Conjugate PDL1V (PF-08046054)
Favorite
S-005
Amivantamab population pharmacokinetics analyses of PALOMA studies supporting the bridging from intravenous formulation to subcutaneous formulation in epidermal growth factor receptor-mutated non-small cell lung cancer
Favorite
S-070
Amplified Bioanalytical Uncertainty Propagation Impact on Population Pharmacokinetic Modeling
Favorite
S-090
An Empirical Drug Autoinduction Model to Characterize the Population Pharmacokinetics of TEV-56286 (Emrusolmin) in Healthy Participants and Patients
Favorite
T-041
An extended Bayesian semi-mechanistic dose-finding design in oncology using pharmacokinetic and pharmacodynamic information
Favorite
M-085
An innovative framework to find potential immunotherapy targets using QSP modeling and RNA-seq data
Favorite
M-106
An Integrated model of Lu-PSMA-617 dose, tumor dosimetry, PSA and OS to enable future study design
Favorite
M-087
An Integrated PK-PD Model to Characterize Circadian-Driven ACTH-Cortisol Interactions in Patients with Congenital Adrenal Hyperplasia
Favorite
M-016
Application of in silico Healthy Control Cohorts in the Analysis of Osivelotor Exposure in Organ Impairment
Favorite
T-052
Application of Neural ODEs for Agnostic Inference of Feedback Mechanism Structure in QSP Models
Favorite
T-019
Application of NSGA-II and pyDarwin in Multi-objective Optimization for Population Pharmacokinetic (PopPK) Model Selection
Favorite
S-019
Applying Mechanistic PKPD Models to Differentiate Inhibitors of Werner Syndrome Helicase Based on Predicted in vivo Target Engagement
Favorite
M-020
Assessment of Drug-Drug Interaction Effect of Gastric Acid Reducing Agents on Lazertinib Exposure in EGFR-Mutated Non-Small Cell Lung Cancer
Favorite
S-071
Assessment of Virtual Control Groups for Organ Impairment Studies Using Population Pharmacokinetic Simulation: Twin Matching versus Group Matching
Favorite
S-046
Assessment of Weight Loss by Amylin Receptor Agonists Alone and In Combination with GLP-1 Receptor Agonists: A Model-Based Meta-Analysis
Favorite
M-091
Auto-Induction and PD-Enhanced TMDD population PK Models for Engineered IL-15 cytokine Efbalropendekin alfa (XmAb24306) in Cancer Therapy
Favorite
S-072
Automated concentration-QT data preparation, model selection and reporting in R
Favorite
S-030
Automated Generation of Computational Models from Scientific Publications Using AI
Favorite
M-060
Automated Model Generation with Delineate Co-Pilot
Favorite
S-073
Automated simulation with parameter uncertainty from R with NONMEM and NMsim_NWPRI
Favorite
